Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales

Simple item page
UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue7
UDC.journalTitleAntimicrobial Agents and Chemotherapy
UDC.startPagee0019526
UDC.volume70
dc.contributor.authorSánchez-Peña, Lucía
dc.contributor.authorRodríguez-Pallares, Salud
dc.contributor.authorBlanco Martín, Tania
dc.contributor.authorPérez-Rodríguez, Gloria
dc.contributor.authorAja-Macaya, Pablo
dc.contributor.authorGonzález-Pinto, Lucía
dc.contributor.authorLópez-Hernández, Inmaculada
dc.contributor.authorAracil, Belén
dc.contributor.authorBeceiro Casas, Alejandro
dc.contributor.authorBou, Germán
dc.contributor.authorArca-Suárez, Jorge
dc.date.accessioned2026-08-20T09:48:13Z
dc.date.available2026-08-20T09:48:13Z
dc.date.issued2026-05-29
dc.descriptionComparative study
dc.description.abstract[Abstract] We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied.
dc.description.sponsorshipThis study was supported by the Instituto de Salud Carlos III (ISCIII) through projects PI21/00704, PI22/01212, PI23/00851, PI24/00920, and PI25/00116 co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CB21/13/00055). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Economía, Emprego e Industria, and Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/08 to J.A.-S.). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). T.B.-M. was financially supported by the ISCIII Río Hortega program (CM23/00095). G.P.-R. was supported by PI22/01212 and GAIN-Xunta de Galicia (IN606A 2025/020). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026).
dc.identifier.citationSánchez-Peña L, Rodríguez-Pallares S, Blanco-Martín T, Pérez-Rodríguez G, Aja-Macaya P, González-Pinto L, López-Hernández I, Aracil García B, Beceiro A, Bou G, Arca-Suárez J. Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother. 2026 Jul;70(7):e0019526.
dc.identifier.doi10.1128/AAC.00195-26
dc.identifier.issn1098-6596
dc.identifier.urihttps://hdl.handle.net/2183/49057
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PI21%2F00704/ES/VACUNAS AUXOTROFAS ORALES PARA LA ERRADICACION DE BACTERIAS INTESTINALES: COLONIZACIÓN INTESTINAL POR KLEBSIELLA PNEUMONIAE MULTIRRESISTENTE COMO MODELO/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI22%2F01212/ES/Inhibidores de carbapenemasas: actividad frente a Enterobacterales productores de carbapenemasas, mecanismos e impacto en la evolución de la resistencia antimicrobiana (PROTECT)/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI23%2F00851/ES/Actividad in vivo de nuevos inhibidores de carbapenemasas frente a patógenos críticos multirresistentes: K. pneumoniae productor de carbapenemasas y P. aeruginosa./
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI24%2F00920/ES/Vacunas versátiles basadas en ARN para combatir las infecciones causadas por cepas multirresistentes de Pseudomonas aeruginosa/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2024-2027/PI25%2F00116/ES/Medicina personalizada frente a Gram negativos prioritarios: posicionamiento de nuevos ß-lactámicos, evolución dirigida del resistoma y diagnóstico de precisión con MALDI-TOF y machine learning/
dc.relation.urihttps://doi.org/10.1128/AAC.00195-26
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectEnterobacterales
dc.subjectAvibactam
dc.subjectCarbapenemase
dc.subjectCarbapenemase-producing Enterobacterales
dc.subjectCeftibuten
dc.subjectLedaborbactam
dc.subjectXeruborbactam
dc.subjectβ-lactam
dc.subjectβ-lactamase
dc.subjectβ-lactamase inhibitor
dc.titleComparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
SPena_Comparative_2026.pdf
Size:
566.6 KB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
SPena_Comparative_2026_Suppl.docx
Size:
123.39 KB
Format:
Microsoft Word XML
Description:
Supplementary material
Download

Collections

Investigación (FFISIO)